Exploratory Study of Bioactive Adrenomedullin as a Potential Biomarker for Severe Infections in Emergency Department Patients
-
By
-
Constantin Maier-Stocker
-
Julian Hupf
-
Jillena Zinsser-Krys
-
Markus Zimmermann
-
Frank Hanses
-
February 28, 2026
-
Clinical Scorecard: Exploratory Study of Bioactive Adrenomedullin as a Potential Biomarker for Severe Infections in Emergency Department Patients
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | |
| Target Population | Patients aged 18 and older presenting to the ED with suspected severe infections, including specific conditions. |
| Care Setting | |
Key Highlights
- Bio-ADM levels correlate with sepsis severity and mortality rates.
- Point-of-care testing for bio-ADM can enhance sepsis diagnostics.
- Elevated bio-ADM levels indicate higher odds for mortality and multi-organ failure.
- Consideration of limitations in bio-ADM testing.
Guideline-Based Recommendations
Diagnosis
Management
- Early identification and management of sepsis are critical to reduce mortality.
- Implement specific management strategies based on bio-ADM levels.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Bio-ADM may serve as a therapeutic target and prognostic indicator, requiring further clarification.
Clinical Best Practices
- Implement point-of-care bio-ADM testing for rapid assessment of sepsis risk.
- Adhere to established protocols for early sepsis recognition and treatment.
- Incorporate evidence-based practices for monitoring bio-ADM levels.
References
